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Purpose: Quality-of-life (QoL) scores in chronic obstructive pulmonary disease (COPD) have 
a weak relationship with physiologic impairment. We investigated factors associated with poor 
QoL, focusing on psychological measures potentially amenable to intervention.
Patients and methods: We utilized a pre-existing Birmingham (UK) COPD cohort to assess 
factors associated with QoL impairment (COPD Assessment Test [CAT] scores). Univariate and 
multivariate regression models were constructed from three categories of variables: demographic, 
lung function/COPD-related symptoms, and psychosocial/behavioral factors.
Results: Analyses were based on self-report questionnaire data from 735 participants. The 
multivariate model of variables independently associated with CAT included depression, 
dysfunctional breathing symptoms (Nijmegen score), and illness perception, in addition to COPD 
symptoms (wheeze, cough), exercise capacity, breathlessness, exacerbations, and deprivation; 
this model explained 72% of CAT score variation. In a dominance analysis assessing the relative 
contribution of variables, similar contributions were made by breathlessness (20.2%), illness 
perception (19.8%), dysfunctional breathing symptoms (17.5%), and depression (12.5%) with 
other variables contributing ,5%.
Conclusion: Psychological factors significantly contribute to disease-specific QoL impairment 
in COPD, and potentially explain the mismatch between objective physiologic impairment 
and patients’ experience of their disease. Interventions targeting psychological factors, illness 
perception, and dysfunctional breathing should be assessed.
Keywords: chronic obstructive pulmonary disease, quality of life, health status, survey, psy-
chological, dysfunctional breathing, breathlessness, illness perception, depression
Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality and a global public health problem.1 As a complex, multifaceted disease, 
it affects patients in many ways and results in significant quality-of-life (QoL) 
impairment.2 However, QoL varies greatly between individuals, and is only weakly 
associated with physiologic factors such as percentage predicted forced expiratory 
volume in 1 second (FEV
1
).3 Anxiety and depression are common, although frequently 
unrecognized and untreated,4 and are associated with poor COPD outcomes.5–7 Previous 
research suggests that a variety of disease-related and patient-related factors may be 
associated with QoL impairment in COPD.3 In addition to biologic factors (such as 
lung function and inflammation) and demographic/socioeconomic factors, there is evi-
dence that QoL is affected by comorbidities, particularly psychological conditions,8–11 
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and by psychological constructs such as illness perception.12 
The relative importance of these different factors is cur-
rently unclear.
Understanding the determinants of QoL impairment 
in COPD may highlight modifiable factors that could be 
targeted to minimize disease impact and to help patients 
to cope better with the consequences of having an incur-
able long-term condition. In particular, psychological and 
behavioral interventions may be appropriate for selected 
patients. Nonpharmacologic interventions are acceptable to 
many patients, particularly those with significantly impaired 
QoL and those with “disproportionate” QoL impairment 
in relation to their lung function impairment.13 The impor-
tance of a “personalized medicine” strategy for managing 
airways disease has recently been emphasized, aiming 
to target appropriate treatments, both pharmacologic and 
nonpharmacologic, on potentially modifiable factors in well-
characterized individual patients.14 We hypothesized that a 
range of psychological, social, perceptual, and behavioral 
factors, measured using validated patient-reported outcome 
measures, would be independently associated with QoL in 
patients with COPD.
Methods
study design
We report a cross-sectional analysis of data from the 
Birmingham COPD cohort study.15 The current analysis 
investigated factors independently influencing disease-spe-
cific QoL (assessed by the COPD Assessment Test [CAT])16 
and generic health-related (HR) QoL score using the 5 level 
EuroQoL questionnaire (EQ-5D 5L),17 and estimated the 
magnitude of contribution of different contributory factors, 
with a particular focus on clarifying the relative contribution 
of psychosocial and behavioral factors.
subjects and setting
The Birmingham COPD cohort study is described fully 
elsewhere,18 but briefly consists of three patient groups 
recruited from 71 primary care practices in the West Midlands, 
UK during the period May 2012–June 2014: 1) patients with 
diagnosed COPD on general practitioner registers; 2) newly 
identified COPD patients from a linked case-finding study;15 
and 3) participants from the case-finding study with chronic 
respiratory symptoms but without airflow obstruction. Cohort 
participants were characterized at baseline with a series of 
questionnaires and objective measurements (including the 
Medical Research Council [MRC] breathlessness scale,19 
assessments of lung function, muscle strength, and exercise 
capacity as sit/stand repetitions with Borg breathlessness 
scores20 pre- and post-exercise). Cohort participants were 
invited to complete review questionnaires at 6-monthly 
intervals for 3 years including items regarding health, life-
style, health-related quality of life (HRQoL), exacerbations, 
health care usage, and medical conditions; health resource 
use information was also collected. At the time of this 
analysis, the full cohort consisted of 2,188 patients. Ethical 
approval was provided by the National Research Ethics 
Service Committee, West Midlands, Solihull, UK (ref: 11/
WM/0304). All participants provided written informed 
consent for this study.
For the purposes of the current analysis, an additional 
questionnaire set was administered at one time point per 
patient, assessing symptoms of dysfunctional breathing 
(Nijmegen questionnaire),21 depression (PHQ-9),22 anxiety 
(GAD-7),23 illness perceptions (Brief Illness Perception 
Questionnaire, IPQ),24 and agoraphobic avoidance.25 Ques-
tionnaires were posted to participants with an explanatory 
letter and a return envelope, with one reminder sent 2 weeks 
after the initial mailing.
Patients were included in our analysis if they 1) had an 
existing COPD diagnosis or were identified from the case-
finding trial and 2) met the spirometric criteria for COPD, 
based on UK guideline definitions (FEV
1
/FVC [forced vital 
capacity] ,0.7) at the baseline assessment.
statistical methods
Descriptive statistics are reported on all variables. Univariate 
associations between disease-specific QoL (CAT score) and 
other variables were analyzed using linear regression. Initially 
we fitted univariate regression models to determine which 
variables were significantly associated with CAT at the 5% 
level. These variables were taken forward into multivariate 
regression models to determine which were independently 
predictive in mutually adjusted analyses. We considered 
variables within three categories: 1) demographic charac-
teristics (age, sex, body mass index [BMI], socioeconomic 
status [Index of Multiple Deprivation {IMD}, as quintiles],26 
employment status, comorbidity); 2) COPD-related factors 
(FEV
1
% predicted, physical activity, chronic cough/phlegm, 
chronic wheeze, breathlessness, exacerbations, hospitaliza-
tions); and 3) psychosocial and behavioral factors (anxiety, 
depression, dysfunctional breathing symptoms, illness per-
ception, agoraphobic avoidance).
Those variables that were independently predictive of 
CAT score at the 5% significance level within each of these 
categories were taken forward in a final regression model to 
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determine which variables were independently predictive 
overall, and to explore whether psychological measures 
had an association with CAT score independent of patient 
characteristics and COPD-related symptoms. In the multi-
variate models, only cases without missing data in any field 
were included and none of the missing data were imputed. 
Although this does result in a reduction in the sample size, 
as the purpose of this study was to explore the relationship 
between variables and to determine which were most highly 
predictive of HRQoL, it was important that participants con-
tributed data on all variables. A multiple imputation model 
would have required some assumption of the likely distribu-
tion of missing values and might have introduced bias into 
our exploratory analysis by imposing a likely relationship 
between variables and between the variables and HRQoL.
The R-squared value was used in order to quantify the 
extent to which the variables explained the variation in CAT 
score. To determine the contribution that each predictor made 
to the overall variance, and therefore their relative impor-
tance, a dominance analysis was undertaken.27 Dominance 
analysis examines the change in R-squared from adding a 
variable to all possible subset regression models and then 
averaging across all possible models. In this way, it is possible 
to obtain a general dominance weight and thereby partition 
the R-squared value among the predictors. All variables that 
were significant in their respective categories were included 
in the dominance analysis.
A further analysis was conducted using the same method-
ology with generic HR QoL score EQ-5D 5L rather than the 
disease-specific CAT score as the outcome variable.
Analyses were carried out in Stata v14 (StataCorp. 2015. 
Stata Statistical Software: Release 14. College Station, TX: 
StataCorp LP).
Results
eligible population
One thousand six hundred three cohort participants meeting 
entry criteria and with valid spirometry readings were posted 
the additional questionnaire sets, and 1,233 were returned 
(76.9%). Of these, 181 were excluded from analysis as they 
did not have obstructive spirometry (FEV
1
/FVC ratio ,0.70), 
and a further 317 as they did not have a valid CAT score, 
leaving an analysis sample of 735 participants (consisting of 
599 previously diagnosed COPD subjects and 136 identified 
through case finding). The case-found patients had milder 
disease, with better-preserved lung function, less breath-
lessness, chronic cough and wheeze, and a history of fewer 
exacerbations (Table 1).
A large variation in CAT score was observed (mean, SD 
CAT score 17.9, 8.3). Case-found participants reported less 
COPD impact compared to those with diagnosed COPD 
(14.0, 7.6 vs 18.7, 8.2, respectively).
Univariate and multivariate associations 
with COPD-related Qol
Demographic characteristics
Four patient characteristics were significantly associated 
with higher CAT score: higher level of deprivation (IMD 
status), being currently unemployed, younger age, and being 
a current smoker (Table 2). Although these associations were 
statistically significant at the 5% level, the R-squared values 
were low. The highest R-squared value was for depriva-
tion and even that explained only 5.7% of the variation in 
CAT scores.
lung function and COPD-related symptoms
The independent predictors in this category were chronic 
wheeze, chronic cough/phlegm, exercise capacity at base-
line (sit/stand repetitions), MRC score, Borg breathlessness 
pre- and post-exercise scores, and having $2 exacerbations 
in the previous 12 months (Table 3). The MRC score was 
the strongest predictor, explaining 46% of the variation in 
CAT score in this category of factors. The other variables 
explained no more than 16% each, with lung function impair-
ment (% predicted FEV
1
) independently explaining under 
6% of CAT variation in this category group.
Psychosocial and behavioral factors
The PHQ-9 (measuring depression), Nijmegen question-
naire (measuring symptoms of dysfunctional breathing), 
and the brief IPQ (measuring illness perceptions) were all 
significantly associated with CAT in this group of factors, 
and explained 34%, 38%, and 45% of the variance in CAT, 
respectively. Anxiety (GAD-7) scores were not significantly 
independently associated and agoraphobic avoidance scores 
were only weakly associated (Table 4).
Full multivariate model and dominance analysis
A full multivariate model was constructed including all 
variables independently associated with CAT from each 
category (Table 5). This model only included people without 
missing data for any variable (n=476). In this model, depres-
sion (PHQ9), dysfunctional breathing symptoms (Nijmegen 
score), illness perception (IPQ), symptoms of both chronic 
wheeze and chronic phlegm/cough, exercise capacity (sit/
stand repetitions), breathlessness (MRC score and Borg score 
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post-exercise), having $2 exacerbations in the previous year, 
and deprivation (IMD quintile) were all significantly associ-
ated with CAT at the 5% level. This model explains 72.2% 
of the observed variation in CAT.
In the dominance analysis, the largest contributions to 
variation in CAT scores were made by functional breathless-
ness (MRC score, 20.2% of R-squared value), with illness 
perception (IPQ) providing only a slightly lower contribution 
Table 1 Baseline characteristics
Characteristics Previously 
diagnosed (n=599)
Case found 
(n=136)
Total 
(n=735)
Mean CaT score (sD) 18.7 (8.2) 14.0 (7.6) 17.9 (8.3)
CaT score ,10 (%) 133 (22.2) 63 (46.3) 196 (26.7)
CaT score 10–20 (%) 254 (42.40) 58 (42.7) 312 (42.5)
CaT score .20 (%) 212 (35.4) 15 (11.0) 227 (30.9)
Predicted FeV1 (%) 66.1 (20.8) 84.7 (15.6) 69.6 (21.2)
severe COPDa (%) 137/599 (22.9) 1/136 (0.7) 138/735 (18.9)
Male (%) 401/599 (66.9) 83/136 (61.0) 484/735 (65.9)
age 68.9 (8.4) 65.4 (8.6) 68.3 (8.5)
BMI (%)
normal 144/586 (24.6) 26/121 (21.5) 170/707 (24.1)
Underweight 11/586 (1.9) 2/121 (1.7) 13/707 (1.8)
Overweight 251/586 (42.8) 47/121 (38.8) 298/707 (42.2)
Obese 180/586 (30.7) 46/121 (38.0) 226/707 (32.0)
Current working status (%)
employed 62/590 (10.5) 33/135 (24.4) 95/725 (13.1)
Unemployed 167/590 (28.3) 28/135 (20.7) 195/725 (26.9)
retired 361/590 (61.2) 74/135 (54.8) 435/725 (60.0)
IMD score quintile (%)
1 (most deprived) 129/599 (21.5) 31/136 (22.8) 160/735 (21.8)
2 155/599 (25.9) 33/136 (24.3) 188/735 (25.6)
3 95/599 (15.9) 34/136 (25.0) 129/735 (17.6)
4 126/599 (21.0) 20/136 (14.7) 146/735 (19.9)
5 (least deprived) 94/599 (15.7) 18/136 (13.2) 112/735 (15.2)
Physical activity (IPaQ) score (%)
low 189/476 (39.7) 35/120 (29.2) 224/596 (37.6)
Moderate 181/476 (38.0) 42/120 (35.0) 223/596 (37.4)
high 106/476 (22.3) 43/120 (35.8) 149/596 (25.0)
Cough/phlegm for .3 consecutive months/year 384/596 (64.4) 75/135 (55.6) 459/731 (62.8)
Wheeze for consecutive months/year (%) 450/596 (75.5) 83/135 (61.5) 533/731 (72.9)
exacerbations in the past 12 monthsb (%)
none 215/583 (36.9) 89/129 (69.0) 304/712 (42.7)
One 121/583 (20.8) 22/129 (17.1) 143/712 (20.1)
Two or more 247/583 (42.4) 18/129 (14.0) 265/712 (37.2)
respiratory hospitalization in the last 6 months (%) 57/585 (9.7) 5/129 (3.9) 62/714 (8.7)
smoking (%)
Current smoker 144/571 (25.2) 50/129 (38.7) 194/700 (27.7)
ex-smoker 373/571 (65.3) 64/129 (49.6) 437/700 (62.4)
never smoked 54/571 (9.5) 15/129 (11.6) 69/700 (9.9)
Comorbidityc (%) 88/549 (16.0) 21/127 (16.5) 109/676 (16.1)
exercise capacity (sit-to-stand repetition) 18.4 (5.9) 21.4 (6.8) 19.0 (6.1)
Muscle strength (grip strength) 29.7 (10.2) 31.7 (11.5) 30.0 (10.5)
MrC score (%)
1 110/579 (19.0) 52/133 (39.1) 162/712 (22.8)
2 148/579 (25.6) 40/133 (30.1) 188/712 (26.4)
3 144/579 (24.9) 31/133 (23.3) 175/712 (24.6)
4 81/579 (14.0) 6/133 (4.5) 87/712 (12.2)
5 96/579 (16.6) 4/133 (3.0) 100/712 (14.0)
Notes: aFeV1 ,50% predicted. 
bExacerbations defined based on reported prescriptions for antibiotics or steroids for the participant’s lung condition. cComorbidity defined 
as reported diagnosis of one or more of cancer, diabetes, cardiovascular disease, osteoporosis, fracture, and depression.
Abbreviations: BMI, body mass index; CaT, COPD assessment Test; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; 
IMD, Index of Multiple Deprivation; IPaQ, International Physical activity Questionnaire; MrC, Medical research Council.
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(19.8%). Dysfunctional breathing symptoms (Nijmegen 
questionnaire, 17.5%) and depression (PHQ9, 12.5%) were 
the next most important contributors to the CAT variation, 
and other variables contributed 5% or less.
analysis using generic hrQol (eQ-5D 5l)
A further analysis was performed with generic QoL score 
(EQ-5D 5L) as the outcome measure (Table 6). Generally, 
the same variables emerged as important predictors, although 
measures of depression (PHQ-9) and anxiety (GAD-7) were 
more strongly associated with EQ-5D 5L than with CAT 
scores. This model predicted 60.4% of the variation in the 
EQ-5D 5L, with the largest contributions made by depres-
sion (PHQ-9, 23.1%), functional breathlessness (MRC score, 
20.1%), illness perception (IPQ, 16.0%), anxiety (GAD-7, 
14.0%), and symptoms of dysfunctional breathing (Nijmegen 
score, 13.3%). The other significant variables (exercise capac-
ity, BMI, physical activity levels, breathlessness pre-exercise, 
smoking status, deprivation, chronic wheeze, and employ-
ment status) all made smaller contributions (5% or less).
Discussion
The stimulus for this study was the observation that there 
is a large discrepancy at an individual level between the 
objective, biologic severity of COPD and the impact of the 
disease on the patient, as assessed by functional impairment 
and effects on QoL. We aimed to assess and quantify the 
relative contributions of psychosocial and behavioral factors 
on QoL, in order to identify candidate targets for future 
interventions. In this cohort of community-based patients pre-
dominantly having physiologically mild-to-moderate COPD, 
we observed a wide variation in disease-related QoL scores, 
with a mean (SD) CAT score of 17.9 (8.3). The reference 
values for CAT scores suggest that a score of ,10 indicates 
low impact, 10–20 moderate impact, and .20 high impact,28 
showing that the patients in our cohort spanned a wide range 
of perceived QoL impairment from their COPD, ranging from 
low to very high impact. As in previous research, a weak 
relationship was observed between physiologically assessed 
lung function and QoL.29
We found, unsurprisingly, that a major independent 
contribution to impaired QoL came from functional, activity-
related breathlessness, with the MRC breathlessness score 
explaining 20% of the variation in both disease-specific 
(CAT) and generic QoL scores (EQ-5D 5L). However, we 
also found that both pessimistic health beliefs (as measured 
by the validated IPQ) and depressed psychological state 
(assessed by the PHQ-9) have major independent impacts on 
Table 2 Patient demographic characteristics associated with CaT score
Characteristics Univariate difference 
in CAT vs reference 
group (95% CI)
p-value Proportion of 
CAT explained 
(R-squared value)
Multivariate difference 
in CAT vs reference 
group (95% CI)
p-value
Male −1.13 (−2.52, 0.25) 0.108 0.004
age −0.10 (−0.18, −0.03) 0.009 0.009 −0.002 (−0.10, 0.10) 0.969
BMI
normal reference 0.014 reference
Underweight 2.48 (−2.61, 7.57) 0.340 0.19 (−4.67, 5.06) 0.938
Overweight −0.27 (−1.97, 1.43) 0.756 0.26 (−1.49, 2.01) 0.770
Obese 2.08 (0.29, 3.88) 0.023 1.73 (−0.10, 3.58) 0.064
Comorbid condition −0.13 (−2.00, 1.73) 0.889 0.000 −0.01 (−1.83, 1.82) 0.993
Current working status
employed reference 0.026 reference
Unemployed 7.11 (4.96, 9.26) ,0.001 6.21 (3.89, 8.53) ,0.001
retired 1.83 (−0.10, 3.78) 0.064 2.12 (−0.13, 4.50) 0.064
IMD score quintile
1 (most deprived) reference 0.057
2 −2.82 (−4.70, −0.96) 0.003 −1.69 (−3.73, 0.34) 0.103
3 −4.89 (−6.94, −2.83) ,0.001 −3.71 (−5.90, −1.51) 0.001
4 −5.14 (−7.12, −3.15) ,0.001 −4.02 (−6.15, −1.88) ,0.001
5 (least deprived) −6.09 (−8.22, −3.94) ,0.001 −4.31 (−6.61, −2.01) ,0.001
smoking
Current smoker reference 0.026 reference
ex-smoker −2.45 (−3.96, −0.94) 0.001 −1.60 (−3.28, 0.06) 0.059
never smoked −5.05 (−7.50, −2.59) ,0.001 −4.25 (−6.83, −1.68) 0.001
Abbreviations: BMI, body mass index; CaT, COPD assessment Test; IMD, Index of Multiple Deprivation.
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patients’ experience of their COPD, explaining 20% and 
12%, respectively, of the variation in CAT scores and high 
proportions (16% and 23%, respectively) of the variation in 
EQ-5D 5L. In addition, we found that dysfunctional breathing 
(measured by the Nijmegen Questionnaire) independently 
explained a large proportion of QoL variability (17% of CAT 
and 13% of EQ-5D 5L). All these factors are potentially 
amenable to intervention. Overall, the models we constructed 
explained over 70% of the variation in disease-specific QoL 
and over 60% of that in generic QoL.
Our findings are in keeping with other smaller studies 
suggesting that psychological factors and illness perceptions 
are important determinants of well-being, overshadowing 
the influence of “harder” factors such as lung function in 
COPD.3,8,12,30,31 Illness perception is a construct of the cogni-
tive representations and beliefs that patients have about their 
illness, and has been found to be an important determinant 
of behavior and to be associated with a number of important 
outcomes, including treatment adherence and functional 
recovery.32 The Brief IPQ is a widely used and validated 
Table 3 COPD-related factors associated with CaT score
Related factors Univariate difference 
in CAT vs reference 
group (95% CI)
p-value Proportion of 
CAT explained 
(R-squared value)
Multivariate difference 
in CAT vs reference 
group (95% CI)
p-value
% predicted FeV1 −0.10 (−0.13, −0.07) ,0.001 0.056 −0.004 (−0.03, 0.02) 0.763
Physical activity (IPaQ)
low reference 0.051 reference
Moderate −3.27 (−4.87, −1.66) ,0.001 0.21 (−0.99, 1.40) 0.730
high −4.91 (−6.71, −3.11) ,0.001 −0.34 (−1.71, 1.04) 0.632
Chronic cough/phlegm 4.89 (3.56, 6.21) ,0.001 0.067 3.11 (2.05, 4.18) ,0.001
Chronic wheeze 6.25 (4.84, 7.67) ,0.001 0.094 2.54 (1.37, 3.71) ,0.001
exercise capacity (sit-to-stand repetition) −0.54 (−0.64, −0.44) ,0.001 0.132 −0.11 (−0.20, −0.02) 0.014
Muscle strength (grip strength) −0.13 (−0.19, 0.07) ,0.001 0.022 −0.04 (−0.09, 0.01) 0.088
MrC score
1 reference 0.461 reference
2 5.04 (2.56, 6.52) ,0.001 3.24 (1.73, 4.76) ,0.001
3 7.67 (6.24, 9.11) ,0.001 5.77 (4.24, 7.28) ,0.001
4 12.46 (11.00, 13.91) ,0.001 8.89 (7.19, 10.59) ,0.001
5 18.76 (17.14, 20.38) ,0.001 13.34 (11.28, 15.40) ,0.001
12-month exacerbationsa
none reference 0.098 reference
One 2.72 (1.00, 4.44) 0.002 0.79 (−0.55, 2.13) 0.247
Two or more 6.44 (5.02, 7.87) ,0.001 2.16 (0.96, 3.36) ,0.001
respiratory hospitalization in the last 6 
months
3.47 (1.11, 5.83) 0.004 0.010 0.45 (−1.34, 2.25) 0.621
Borg breathlessness
Pre-sit/stand test 2.17 (1.83, 2.61) ,0.001 0.146 0.50 (0.11, 0.90) 0.012
Post-sit/stand test 2.15 (1.79, 2.50) ,0.001 0.163 0.51 (0.12, 0.89) 0.011
Note: aExacerbations were defined based on reported prescriptions for antibiotics or steroids for the participant’s lung condition over the previous 12 months.
Abbreviations: CaT, COPD assessment Test; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; IPaQ, International Physical 
activity Questionnaire; MrC, Medical research Council.
Table 4 Psychosocial factors associated with CaT score
Univariate CAT 
vs reference 
group (95% CI)
p-value Proportion of 
HRQoL explained 
(R-squared)
Multivariate difference 
in CAT vs reference 
group (95% CI)
p-value
lubben social network scale −0.14 (−0.26, −0.02) 0.020 0.008 0.05 (−0.05, 0.14) 0.313
anxiety (gaD-7) 0.88 (0.75, 1.02) ,0.001 0.215 −0.10 (−0.28, 0.09) 0.313
Depression (PhQ-9) 0.98 (0.88, 1.08) ,0.001 0.342 0.29 (0.11, 0.47) 0.002
agoraphobic avoidance scale 6.01 (4.63, 7.38) ,0.001 0.097 1.32 (0.09, 2.54) 0.035
nijmegen questionnaire 12.56 (11.29, 13.83) ,0.001 0.375 6.88 (5.33, 8.42) ,0.001
Brief IPQ 0.46 (0.42, 0.50) ,0.001 0.445 0.28 (0.23, 0.34) ,0.001
Abbreviations: CaT, COPD assessment Test; COPD, chronic obstructive pulmonary disease; gaD-7, general anxiety Disorder assessment; hrQol, health-related 
quality of life; IPQ, Illness Perception Questionnaire; PhQ-9, Patient health questionnaire.
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tool with good psychometric properties.33 There is limited 
research linking poor illness perception with disability and 
impaired QoL in COPD,34 and no interventional studies 
that we are aware of. There is emerging evidence that brief, 
straightforward psychoeducational interventions can help 
to modify negative illness beliefs and lead to improvements 
over a range of different health outcomes.35 In view of the 
findings we report in this study, there is a case for developing 
interventional studies based on strategies to improve illness 
perception in COPD.
There is consistent evidence that depression and anxiety 
are common comorbidities in patients with COPD and are 
associated with poor outcomes.3–10,36,37 There is, however, 
surprisingly little evidence to support the use of psychological 
interventions in managing COPD, or to clarify which inter-
ventions are most effective and acceptable.38 Although there 
is some preliminary evidence to support interventions such as 
relaxation, cognitive behavioral therapy, self-management, 
and antidepressant medication in COPD, the data are limited 
and mainly consisted of small studies.38 Qualitative evidence 
suggests that psychological interventions are acceptable to 
COPD patients with disproportionately impaired QoL in rela-
tion to lung function impairment, particularly interventions 
based on nonpharmacologic strategies.13 Our finding that a 
large proportion of QoL variation is explained by psychologi-
cal factors supports the need for interventional studies.
A novel contribution of this study was to include a mea-
sure of dysfunctional breathing, the Nijmegen Questionnaire, 
Table 5 Multivariate associations with CAT score – all significant variables (n=476)
Difference in CAT 
vs reference group 
(95% CI)
p-value Contribution 
to R-squared 
value 
Proportion 
of R-squared 
explained, %
Ranking
MrC score at baseline 0.144 20.2 1
1 reference
2 2.97 (1.63, 4.31) ,0.001
3 3.94 (2.55, 5.32) ,0.001
4 4.46 (2.83, 6.09) ,0.001
5 7.02 (5.04, 9.00) ,0.001
Brief IPQ 0.16 (0.12, 0.21) ,0.001 0.142 19.8 2
nijmegen score 4.72 (3.41, 6.02) ,0.001 0.125 17.5 3
Depression (PhQ-9) 0.19 (0.07, 0.31) 0.002 0.09 12.5 4
exercise capacity (sit-to-stand repetition) −0.13 (−0.22, −0.05) 0.001 0.038 5.3 5
Borg breathlessness 0.42 (0.07, 0.76) 0.017 0.037 5.1 6
12-month exacerbationsa 0.029 4.0 7
none reference
One 1.49 (0.29, 2.69) 0.015
Two or more 1.73 (0.67, 2.80) 0.001
Chronic wheeze 1.71 (0.64, 2.79) 0.002 0.024 3.4 8
IMD score quintile 0.024 3.3 9
1 (most deprived) reference
2 −1.31 (−2.63, 0.004) 0.051
3 −2.01 (−3.51, −0.52) 0.008
4 −2.44 (−3.82, −1.05) 0.001
5 (least deprived) −2.81 (−4.28, −1.34) ,0.001
Chronic cough/phlegm 1.90 (0.94, 2.87) ,0.001 0.021 2.9 10
Borg breathlessness pre-sit/stand test −0.24 (−0.58, 0.11) 0.175 0.017 2.4 11
agoraphobic avoidance 0.09 (−0.92, 1.10) 0.864 0.02 2.2 12
smoking 0.01 1.2 13
Current smoker reference
ex-smoker 0.02 (−1.07, 1.12) 0.967
never smoked −0.75 (−2.44, 0.95) 0.388
Current working status 0.001 0.1 14
employed reference
Unemployed 0.68 (−0.80, 2.16) 0.368
retired 0.01 (−1.33, 1.34) 0.994
Note: aExacerbations were defined based on reported prescriptions for antibiotics or steroids for the participant’s lung condition over the previous 12 months.
Abbreviations: CaT, COPD assessment Test; COPD, chronic obstructive pulmonary disease; gaD-7, general anxiety Disorder assessment; IMD, Index of Multiple 
Deprivation; IPQ, Illness Perception Questionnaire; MrC, Medical research Council; PhQ-9, Patient health questionnaire.
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Table 6 Multivariate associations with EQ-5D 5L – all significant variables (n=375)
Difference in EQ-5D 
5L vs reference 
group (95% CI)
p-value Contribution 
to R-squared 
value
Proportion 
of R-squared 
explained, %
Ranking
Depression (PhQ-9) −0.01 (−0.02, −0.01) ,0.001 0.139 23.1 1
MrC score at baseline 0.121 20.1 2
1 reference
2 −0.04 (−0.08, −0.004) 0.003
3 −0.05 (−0.09, −0.01) 0.012
4 −0.10 (−0.15, −0.06) ,0.001
5 −0.16 (−0.22, −0.10) ,0.001
Brief IPQ −0.002 (−0.004, −0.001) 0.001 0.096 16.0 3
anxiety (gaD-7) −0.006 (−0.01, −0.001) 0.009 0.085 14.0 4
Dysfunctional breathing (nijmegen scale) −0.06 (−0.10, −0.01) 0.008 0.080 13.3 5
exercise capacity (sit-to-stand repetition) at baseline 0.002 (−0.0004, 0.0005) 0.097 0.029 4.8 6
BMI 0.014 2.2 7
normal reference
Underweight −0.07 (−0.16, 0.02) 0.151
Overweight −0.03 (−0.07, 0.004) 0.080
Obese −0.04 (−0.08, −0.01) 0.021
Physical activity (IPaQ) score 0.013 2.2 8
low reference
Moderate 0.03 (0.002, 0.06) 0.032
high 0.02 (−0.02, 0.06) 0.269
Borg breathlessness pre-sit/stand test 0.002 (−0.007, 0.01) 0.670 0.013 2.1 9
smoking 0.005 0.9 10
Current smoker reference
ex-smoker 0.01 (−0.02, 0.04) 0.521
never smoked 0.0003 (−0.05, 0.05) 0.988
IMD score quintile 0.004 0.6 11
1 (most deprived) reference
2 −0.01 (−0.06, 0.03) 0.543
3 0.004 (−0.04, 0.05) 0.858
4 −0.004 (−0.05, 0.04) 0.822
5 (least deprived) −0.01 (−0.06, 0.03) 0.626
Chronic wheeze (wheeze ongoing for 3 consecutive 
months each year)
0.002 (−0.03, 0.03) 0.805 0.003 0.5 12
Current working status 0.002 0.3 13
employed reference
Unemployed −0.01 (−0.05, 0.03) 0.602
retired −0.01 (−0.06, −0.03) 0.523
Abbreviations: BMI, body mass index; gaD-7, general anxiety Disorder assessment; IMD, Index of Multiple Deprivation; IPaQ, International Physical activity 
Questionnaire; IPQ, Illness Perception Questionnaire; MrC, Medical research Council; PhQ-9, Patient health questionnaire; Qol, quality of life; eQ-5D 5l, 5 level euroQol 
questionnaire. 
which was found to be a major contributor to the variation in 
both generic and disease-specific QoL. Although this ques-
tionnaire has not been validated for use in COPD, it has been 
widely used in other airways diseases including asthma,39 with 
breathing retraining interventions shown to improve QoL 
scores.40 The significant independent association of Nijmegen 
Questionnaire score to QoL improvement in patients with 
COPD indicates that breathing retraining may also be a pos-
sible strategy to improve QoL in people with COPD.
A strength of this study was the availability of data from 
a large well-characterized UK COPD cohort, containing a 
relatively representative sample of patients with mild and 
moderate COPD treated in primary care. The large sample 
size, compared with much smaller previous studies (two 
studies had samples of ,100),12,30 and the collection of data 
on a wide panel of disease-related factors allowed us to 
examine the relative contribution of different factors relating 
to QoL impairment in COPD. We were able to include a wide 
range of potential explanatory variables in the models, which 
were more inclusive than those in previous studies. Also, 
unlike previous studies that used only generic QoL tools,31 
we used both generic and disease-specific instruments. 
Similar messages emerged from our study for disease-specific 
and generic QoL instruments.
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A limitation of our study is that it is cross-sectional, 
describing associations between measured factors and QoL 
that cannot be assumed as causal, and there is no certainty that 
interventions targeting these factors will result in clinically 
important improvements in QoL. It does, however, provide 
a justification for future interventional studies targeted on 
improving illness perception, improving depression and 
correcting dysfunctional breathing in COPD patients, par-
ticularly in those with disproportionately impaired QoL in 
relation to lung function impairment.
Conclusion
COPD is a distressing and progressive condition that makes 
life miserable for many, and a holistic and multidimensional, 
personalized approach is needed.14 The clinical focus in 
COPD is generally directed toward biologic factors such as 
physiologic impairment and airways inflammation, with a 
predominant focus on pharmacologic interventions. How-
ever, along with smoking cessation, nonpharmacologic 
approaches are also very important in improving patient 
outcomes, with pulmonary rehabilitation now recognized 
as being a key element in overall disease management. This 
study shows that there are a number of factors associated 
with QoL impairment that could potentially be modified 
through suitable nonpharmacologic interventions focused on 
appropriately characterized patients, and supports the need 
for future interventional studies.
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